Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.
Bottom Line: Secondary outcomes were plasma VEGF-A and central foveal thickness.Patients receiving omega-3s (group 1) had significantly lower levels of vitreal VEGF-A (141.11 ± 61.89 pg/mL) when compared with group 2 (626.09 ± 279.27 pg/mL; P = .036) and group 3 (735.48 ± 216.43 pg/mL; P = .013), but similar levels to group 4 (235.81 ± 33.99 pg/mL; P = .215).This study demonstrated that omega-3 supplementation combined with anti-VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients.
Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: firstname.lastname@example.org.Show MeSH
Related in: MedlinePlus
Mentions: Sixty-three patients were screened for the study. Forty patients were deemed eligible participants and were enrolled at the Department of Ophthalmology Clinic, Maisonneuve-Rosemont Hospital, Montreal, after providing written informed consent (Figure 1). Three cohorts consisted of active wet AMD patients (10 per group) who were eligible for anti-VEGF treatment (bevacizumab 1.25 mg/0.05 mL). They were compared with a non-AMD group with epiretinal membrane (ERM) or macular hole (MH; Figure 1). All participants were nonsmokers with regular consumption less than 1 serving of fish intake per week, according to a food-frequency questionnaire applied during recruitment.30
Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: email@example.com.